Ieuan Clay

Ieuan Clay

Auto-generated profile, based on publicly available information

Ieuan Clay

Evidation Health Inc San Mateo, CA United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Cell Metabolism
Verified
Journal Article
Closed access
MEMarc A. Egerman
Marc A. Egerman
SCSamuel M. Cadena
Samuel M. Cadena
JGJason A. Gilbert
Jason A. Gilbert
AMAngelika Meyer
Angelika Meyer
HNHallie N. Nelson
Hallie N. Nelson
DGDavid J. Glass
David J. Glass

21 August 2015 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CSClaudia Stein
Claudia Stein
ABAnaïs Flore Bardet
Anaïs Flore Bardet
GRGuglielmo Roma
Guglielmo Roma
SBSebastian Bergling
Sebastian Bergling
ICIeuan Clay
Ieuan Clay
ABAndreas Bauer
Andreas Bauer
YAP1 is a major effector of the Hippo pathway and a well-established oncogene. Elevated YAP1 activity due to mutations in Hippo pathway components or YAP1 amplification is observed in several types of human cancers. Here we investigated its genomic binding landscape in YAP1-activated cancer cells, as well as in non-transformed cells. We demonstrate that TEAD transcription factors mediate YAP1 chromatin-binding genome-wide, further explaining their dominant role as primary mediators of YAP1-transcriptional activity. Moreover, we show that YAP1 largely exerts its transcriptional control via distal enhancers that are marked by H3K27 acetylation and that YAP1 is necessary for this chromatin mark at bound enhancers and the activity of the associated genes. This work establishes YAP1-mediated transcriptional regulation at distal enhancers and provides an expanded set of target genes resulting in a fundamental source to study YAP1 function in a normal and cancer setting. The YAP1/Hippo signaling pathway is a key regulator of organ size and tissue homeostasis, and its dysregulation is linked to cancer development. Elevated activity of YAP1, a transcriptional coactivator and well-established oncogene has been reported to occur in human cancers. Comprehensive identification of YAP1 regulated genes and its mode of action will be of high importance to uncover YAP1 biology that could be exploited for a therapeutic intervention. To this end, we performed genome-wide analyses to identify YAP1 occupied sites in cancer cell lines representing different YAP1/Hippo pathway tumor etiologies and in non-transformed fibroblasts. Our data demonstrate that YAP1 activity is mediated predominantly via TEAD transcription factors supporting the importance of TEADs as main mediators of YAP1-coactivator activity. We further show that YAP1 and TEAD1 exert their transcriptional control via binding to enhancers, leading to characteristic chromatin changes and distal activation of genes. By linking enhancers to genes, we provide a list of novel YAP1 target genes in an oncogenic setting that we show can readily be exploited in tumor classification and provides a foundation for further investigations.

19 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ABAdrian Britschgi
Adrian Britschgi
ABAnke Bill
Anke Bill
HBHeike Brinkhaus
Heike Brinkhaus
CRChristopher Rothwell
Christopher Rothwell
ICIeuan Clay
Ieuan Clay
MBMohamed Bentires-Alj
Mohamed Bentires-Alj
The calcium-activated chloride channel anoctamin 1 ( ANO1 ) is located within the 11q13 amplicon, one of the most frequently amplified chromosomal regions in human cancer, but its functional role in tumorigenesis has remained unclear. The 11q13 region is amplified in ∼15% of breast cancers. Whether ANO1 is amplified in breast tumors, the extent to which gene amplification contributes to ANO1 overexpression, and whether overexpression of ANO1 is important for tumor maintenance have remained unknown. We have found that ANO1 is amplified and highly expressed in breast cancer cell lines and primary tumors. Amplification of ANO1 correlated with disease grade and poor prognosis. Knockdown of ANO1 in ANO1-amplified breast cancer cell lines and other cancers bearing 11q13 amplification inhibited proliferation, induced apoptosis, and reduced tumor growth in established cancer xenografts. Moreover, ANO1 chloride channel activity was important for cell viability. Mechanistically, ANO1 knockdown or pharmacological inhibition of its chloride-channel activity reduced EGF receptor (EGFR) and calmodulin-dependent protein kinase II (CAMKII) signaling, which subsequently attenuated AKT, v-src sarcoma viral oncogene homolog (SRC), and extracellular signal-regulated kinase (ERK) activation in vitro and in vivo. Our results highlight the involvement of the ANO1 chloride channel in tumor progression and provide insights into oncogenic signaling in human cancers with 11q13 amplification, thereby establishing ANO1 as a promising target for therapy in these highly prevalent tumor types.

1 July 2015 in Developmental Cell
Verified
Journal Article
Closed access
CGChenguang Gong
Chenguang Gong
ZLZhizhong Li
Zhizhong Li
KRKrishnan Ramanujan
Krishnan Ramanujan
ICIeuan Clay
Ieuan Clay
YZYunyu Zhang
Yunyu Zhang
DGDavid J. Glass
David J. Glass

16 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HRHeinz Ruffner
Heinz Ruffner
JSJoëlle Sprunger
Joëlle Sprunger
OCOlga Charlat
Olga Charlat
JLJuliet Leighton-Davies
Juliet Leighton-Davies
BGBianka Grosshans
Bianka Grosshans
FCFeng Cong
Feng Cong
The Wnt/β-catenin signaling pathbway controls many important biological processes. R-Spondin (RSPO) proteins are a family of secreted molecules that strongly potentiate Wnt/β-catenin signaling, however, the molecular mechanism of RSPO action is not yet fully understood. We performed an unbiased siRNA screen to identify molecules specifically required for RSPO, but not Wnt, induced β-catenin signaling. From this screen, we identified LGR4, then an orphan G protein-coupled receptor (GPCR), as the cognate receptor of RSPO. Depletion of LGR4 completely abolished RSPO-induced β-catenin signaling. The loss of LGR4 could be compensated by overexpression of LGR5, suggesting that LGR4 and LGR5 are functional homologs. We further demonstrated that RSPO binds to the extracellular domain of LGR4 and LGR5, and that overexpression of LGR4 strongly sensitizes cells to RSPO-activated β-catenin signaling. Supporting the physiological significance of RSPO-LGR4 interaction, Lgr4−/− crypt cultures failed to grow in RSPO-containing intestinal crypt culture medium. No coupling between LGR4 and heterotrimeric G proteins could be detected in RSPO-treated cells, suggesting that LGR4 mediates RSPO signaling through a novel mechanism. Identification of LGR4 and its relative LGR5, an adult stem cell marker, as the receptors of RSPO will facilitate the further characterization of these receptor/ligand pairs in regenerative medicine applications.

1 April 2010 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
SSStefan Schoenfelder
Stefan Schoenfelder
ICIeuan Clay
Ieuan Clay
PFPeter Fraser
Peter Fraser